Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Gynecologic Cancer × Neurokinin-1 Receptor Antagonists × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Gynecologic Cancer 1

Interventions

fosaprepitant 1 Prochlorperazine 1 Preoperative Exercise 1 Ondansetron 1 Olanzapine 1 Neurokinin-1 Receptor Antagonists 1 FloSeal Matrix 1 Ferric Oxide, Saccharated 1 Enhanced Recovery After Surgery 1 Dexamethasone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04503668 2025-06-18

Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients

University of Michigan Rogel Cancer Center

Phase 3 Terminated

62 enrolled 16 charts

Gynecologic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡